Study finds chemo drug Taxol doesn't work for most women

By
October 10, 2007 23:46

The widely used chemotherapy drug Taxol does not work for the most common form of breast cancer and helps far fewer patients than has been believed, surprising new research suggests. If further study bears this out, more than 20,000 women each year in the United States alone might be spared the side effects of this drug or similar ones without significantly raising the risk their cancer will return. That would be roughly half of all breast cancer patients who get chemo now. In the study, Taxol did the most good for women who had overactive HER-2 genes - the target of the newer breast cancer drug Herceptin. These women were about 40 percent less likely to have a recurrence if they received Taxol. Conversely, Taxol did not significantly help women whose tumors were HER-2 negative and were being helped to grow by estrogen. This is the most common form of the disease.


Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia

By UNIVERSITY OF MICHIGAN HEALTH SYSTEM

Israel Weather
  • 15 - 27
    Beer Sheva
    18 - 23
    Tel Aviv - Yafo
  • 15 - 23
    Jerusalem
    16 - 22
    Haifa
  • 20 - 36
    Elat
    18 - 28
    Tiberias